Swedish Orphan Biovitrum AB (publ)

DB:B6E Stock Report

Market Cap: €9.4b

Swedish Orphan Biovitrum Valuation

Is B6E undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of B6E when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€99.98
Fair Value
72.8% undervalued intrinsic discount
12
Number of Analysts

Below Fair Value: B6E (€27.2) is trading below our estimate of fair value (€99.98)

Significantly Below Fair Value: B6E is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for B6E?

Key metric: As B6E is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for B6E. This is calculated by dividing B6E's market cap by their current earnings.
What is B6E's PE Ratio?
PE Ratio30.6x
EarningsSEK 3.51b
Market CapSEK 107.56b

Price to Earnings Ratio vs Peers

How does B6E's PE Ratio compare to its peers?

The above table shows the PE ratio for B6E vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average67.4x
BIO3 Biotest
15.8x29.3%€1.4b
FYB Formycon
17.3x22.6%€1.1b
SRT3 Sartorius
210.6x30.1%€14.7b
1SXP SCHOTT Pharma KGaA
25.7x13.7%€3.8b
B6E Swedish Orphan Biovitrum
30.6x17.4%€107.6b

Price-To-Earnings vs Peers: B6E is good value based on its Price-To-Earnings Ratio (30.6x) compared to the peer average (67.4x).

Price to Earnings Ratio vs Industry

How does B6E's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
B6E 30.6xIndustry Avg. 28.6xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: B6E is expensive based on its Price-To-Earnings Ratio (30.6x) compared to the European Biotechs industry average (28.3x).

Price to Earnings Ratio vs Fair Ratio

What is B6E's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

B6E PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio30.6x
Fair PE Ratio20x

Price-To-Earnings vs Fair Ratio: B6E is expensive based on its Price-To-Earnings Ratio (30.6x) compared to the estimated Fair Price-To-Earnings Ratio (20x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst B6E forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€27.20
€31.45
+15.6%
10.3%€34.82€23.94n/a12
Jan ’26€27.66
€31.14
+12.6%
10.6%€34.63€23.81n/a11
Dec ’25€26.42
€31.26
+18.3%
10.9%€35.53€23.83n/a11
Nov ’25€28.18
€30.16
+7.0%
11.2%€35.20€23.61n/a11
Oct ’25€28.10
€28.87
+2.8%
8.9%€32.82€22.17n/a11
Sep ’25€27.90
€28.52
+2.2%
8.5%€32.17€21.73n/a11
Aug ’25€23.90
€28.25
+18.2%
8.9%€31.84€21.51n/a10
Jul ’25€24.86
€29.22
+17.5%
6.2%€32.80€25.26n/a10
Jun ’25€24.58
€27.77
+13.0%
9.4%€32.11€21.87n/a10
May ’25€24.32
€26.97
+10.9%
9.8%€31.45€21.42n/a9
Apr ’25€23.08
€27.69
+20.0%
9.6%€32.25€21.96n/a10
Mar ’25€23.22
€28.37
+22.2%
9.2%€33.02€22.49n/a11
Feb ’25€24.50
€27.94
+14.1%
8.0%€30.49€22.27n/a10
Jan ’25€24.14
€26.61
+10.2%
6.0%€29.12€22.58€27.6610
Dec ’24€21.88
€25.61
+17.0%
7.0%€28.41€22.03€26.4210
Nov ’24€19.77
€24.33
+23.1%
10.0%€27.51€18.79€28.1811
Oct ’24€19.37
€24.57
+26.9%
10.0%€27.97€19.10€28.1011
Sep ’24€17.65
€23.87
+35.2%
10.1%€27.30€18.65€27.9011
Aug ’24€17.70
€25.01
+41.3%
9.8%€28.20€19.26€23.9011
Jul ’24€17.77
€24.57
+38.2%
10.4%€27.84€18.50€24.8610
Jun ’24€18.21
€25.46
+39.8%
10.6%€28.95€19.24€24.5810
May ’24€21.96
€25.41
+15.7%
11.5%€28.75€18.67€24.3210
Apr ’24€21.47
€24.40
+13.7%
9.6%€27.59€19.09€23.089
Mar ’24€21.52
€24.40
+13.4%
9.6%€27.59€19.09€23.229
Feb ’24€20.14
€22.68
+12.6%
12.5%€27.28€18.16€24.509
Jan ’24€19.20
€22.80
+18.8%
11.9%€27.00€18.31€24.1410
Analyst Price Target
Consensus Narrative from 12 Analysts
€31.37
Fair Value
13.3% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 22:22
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Swedish Orphan Biovitrum AB (publ) is covered by 30 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander LindströmABG Sundal Collier
Shirley ChenBarclays
Rosie TurnerBarclays